ArticleACS applied bio materials2025
Copper Oxide Nanorods: Potential Agents against Breast Cancer.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the second most prevalent type of cancer worldwide and the leading cause of cancer-related mortality among women. Despite substantial advancements in scientific research, cancer continues to pose a major challenge due to its high global incidence. While numerous nontargeted therapies have been developed, nanotechnology-based platforms are emerging as a promising future for cancer treatment. In this context, we investigated the in vitro antitumor activity of citrate-coated copper oxide nanorods (CuO-nr, aspect ratio ∼3) against breast cancer cells. The CuO-nr colloids demonstrated stability for over 120 days under ambient conditions, with an average hydrodynamic diameter of 107.1 ± 0.67 nm and a zeta potential of -23.8 ± 1.87 mV. Cell viability assays showed that CuO-nr were minimally harmful to nontumor fibroblast cells but highly cytotoxic to MCF-7 breast cancer cells. Flow cytometry analysis suggested that early apoptosis may be the primary mechanism of cell death induced by these nanoparticles. Furthermore, significant alterations in cell morphology were observed through scanning electron microscopy. These findings indicate that citrate-coated CuO-nr possess effective antitumor activity and hold promise as potential agents for targeted cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.